Company*
(Country;
Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)

Cellegy
Pharmaceuticals
Inc. (OTC BB:CLGY)

ProStrakan Group plc (UK; LSE:PSK)

They renegotiated deal under which ProStrakan distributes the testosterone gel Tostrex in Europe

ProStrakan will assume responsibility for manufacturing and product support and will purchase the product directly from the manufacturer; Cellegy remains entitled to milestone and royalty payments (1/19)

Third Wave
Technologies
Inc. (TWTI)

Chiron Corp. (CHIR) and Bayer Corp.

Lawsuits were dismissed that Third Wave filed over patents related to hepatitis C virus

No licenses were granted or taken under the deal, and no payment was made; terms were not disclosed (2/23)

Third Wave
Technologies
Inc. (TWTI)

Innogenetics NV (Belgium; (Euronext:INNX)

Third Wave got nonexclusive rights to sell hepatitis C virus genotyping products in the U.S.

The agreement resolved patent litigation between the companies; terms were not disclosed (2/9)

MultiCell
Technologies
Inc. (OTC
BB:MCET)

XenoTech LLC*

MultiCell terminated 2003 deal under which XenoTech was entitled to sell sublicenses

The sublicenses covered MultiCell's immortalized human liver cells; MultiCell said minimum royalty requirements were not met (2/6)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.